Nervous System Diseases
Conditions
Interventions
IV cerebrolysin
Standard therapy only which is IV thrombolysis plus mechanical thrombectomy
Sponsors
Ain Shams University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients with acute cardioembolic stroke as defined by TOAST classification. - Evidence of large vessel occlusion - NIHSS =10, - Underwent successful mechanical thrombectomy ± IV thrombolysis, after fulfilling the standard eligibility criteria.
Exclusion criteria
Exclusion criteria: - Patients aged more than 80 years old - Patients with epilepsy - Patients who are pregnant or lactating - Patients serious, advanced, or terminal illness or life expectancy = 6 months - Patients with bleeding tendency or platelet count less than 100,000/uL - Patients with high INR above 1.7 - Patient receiving low molecular weight heparin therapy less than 24 hours of stroke onset. - Patient with premorbid cognitive impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Primary outcome measure will be the overall proportion of subjects receiving Cerebrolysin compared to the control group experiencing a favorable functional outcome (by modified Rankin Scale0–2 and MOCA score) at 90 days, following stroke onset. | — |
Secondary
| Measure | Time frame |
|---|---|
| The Secondary outcomes are to determine the efficacy of Cerebrolysin as compared to the control group in reducing the risk of symptomatic secondary hemorrhagic transformation, improving neurological outcomes(NIHSS 0–2 at day 14, day 30, and 90), reducing mortality rates (over the 90-day). | — |
Countries
Egypt
Contacts
Public ContactAyman El Sudany
Lecturer of neurology Ain Shams university
Outcome results
None listed